Simvastatin Effects on Inflammation and Platelet Activation Markers in Hypercholesterolemia
Table 1
Clinical characteristics of hypercholesterolemic patients at baseline and after two months of treatment with diet alone (control) or simvastatin.
Control (n=20)
Simvastatin (n=25)
Before
After
p-value
Before
After
p-value
Male/Female
M=9 / F=11
-
-
M=11 / F=14
-
-
Age (years)
55±11
-
-
59±13
-
-
BMI (kg/m2)
25±3
25±3
0.4913
25±4
25±4
0.3698
TC (mg/dl)
270±43
269±50
0.8300
282±30
185±27
<0.0001
HDL-C (mg/dl)
47±5
48±4
0.1523
48±9
48±7
0.3851
LDL-C-C (mg/dl)
188±45
185±51
0.7584
196±33
107±25
<0.0001
APO B-100 (mg/dl)
157±17
155±16
0.3153
152±17
93±15
<0.0001
TG (mg/dl)
177±44
175±48
0.7146
190±61
149±43
0.0027
FG (mg/dl)
87±9
85±8
0.3372
88±9
88±8
0.8580
HOMA-IR
2.6±1.3
2.5±1
0.4331
2.6±1.2
2.4±1
0.9678
SBP (mm Hg)
123±7
124±7
0.7199
126±12
125±10
0.2075
DBP(mmHg)
81±6
80±4
0.7239
79±7
79±7
0.9715
Data are presented as mean±SD. TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; APO B, apolipoprotein B; TG, triglycerides; FG; fasting glucose; SBP, systolic blood pressure; DBP, diastolic blood pressure. For p value, paired Student’s t-test or Wilcoxon test was used as appropriate.
